Targeting Trabecular Meshwork Metabolism
Study suggests potential new vitamin B3 treatment for glaucoma protection
A recent eLife study utilized single-cell epigenomic profiling to uncover diversity in trabecular meshwork (TM) cells, highlighting a metabolically vulnerable subtype that suffers mitochondrial dysfunction, contributing to pressure rise in a genetic glaucoma model. Treatment with vitamin B3 (nicotinamide) can counteract this damage, suggesting a new potential therapy for glaucoma. As TM cells have distinct roles, this research indicates that enhancing metabolism in these cells could serve as a novel approach for lowering intraocular pressure and preventing glaucoma progression.
1. Study uncovers diversity in trabecular meshwork cells. 2. TM3 cells show mitochondrial dysfunction linked to glaucoma. 3. Vitamin B3 (nicotinamide) may lower intraocular pressure. 4. Potential dual benefits of nicotinamide for TM cells and optic nerve health. 5. Future research will compare mouse TM cells with human counterparts.
